Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 9, 2013, Pages 4181-4189

  Jones, Scott A ^a   Murakami, Eisuke ^b,c   Delaney, William ^c   Furman, Phillip ^b   Hu, Jianming ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PHARMASSET INC   (United States)

^c GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLEVUDINE; DEOXYGUANOSINE; DNA; ENTECAVIR; NUCLEOTIDE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG MECHANISM; ENZYME ACTIVE SITE; HEPATITIS B VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA BINDING; VIRUS NUCLEOCAPSID;

ADENINE; ARABINOFURANOSYLURACIL; DNA, VIRAL; GUANINE; HEK293 CELLS; HEPATITIS B VIRUS; HUMANS; ORGANOPHOSPHONATES; PROTEIN BINDING; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; VIRAL PROTEINS;

EID: 84882363291     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00599-13     Document Type: Article

References (58)

1. El-Serag HB. 2012. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142:1264-1273.
2. Summers J, Mason WS. 1982. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 29:403-415.
3. Seeger C, Zoulim F, Mason WS. 2007. Hepadnaviruses, p 2977-3030. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed. Lippincott, Williams & Wilkins, Philadelphia, PA.
4. Hu J, Seeger C. 1996. Expression and characterization of hepadnavirus reverse transcriptases. Methods Enzymol. 275:195-208.
5. Lanford RE, Notvall L, Lee H, Beames B. 1997. Transcomplementation of nucleotide priming and reverse transcription between independently expressed TP and RT domains of the hepatitis B virus reverse transcriptase. J. Virol. 71:2996-3004.
6. Lanford RE, Notvall L, Beames B. 1995. Nucleotide priming and reverse transcriptase activity of hepatitis B virus polymerase expressed in insect cells. J. Virol. 69:4431-4439.
7. Jones SA, Boregowda R, Spratt TE, Hu J. 2012. In vitro epsilon RNAdependent protein priming activity of human hepatitis B virus polymerase. J. Virol. 86:5134-5150.
8. Zoulim F, Seeger C. 1994. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J. Virol. 68:6-13.
9. Wang GH, Seeger C. 1992. The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis. Cell 71:663-670.
10. Wang GH, Seeger C. 1993. Novel mechanism for reverse transcription in hepatitis B viruses. J. Virol. 67:6507-6512.
11. Hu J, Anselmo D. 2000. In vitro reconstitution of a functional duck hepatitis B virus reverse transcriptase: posttranslational activation by Hsp90. J. Virol. 74:11447-11455.
12. Hu J, Flores D, Toft D, Wang X, Nguyen D. 2004. Requirement of heat shock protein 90 for human hepatitis B virus reverse transcriptase function. J. Virol. 78:13122-13131.
13. Hu J, Seeger C. 1996. Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase. Proc. Natl. Acad. Sci. U. S. A. 93:1060-1064.
14. Hu J, Toft DO, Seeger C. 1997. Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids. EMBO J. 16:59-68.
15. Bartenschlager R, Schaller H. 1992. Hepadnaviral assembly is initiated by polymerase binding to the encapsidation signal in the viral RNA genome. EMBO J. 11:3413-3420.
16. Nassal M, Rieger A. 1996. A bulged region of the hepatitis B virus RNA encapsidation signal contains the replication origin for discontinuous first-strand DNA synthesis. J. Virol. 70:2764-2773.
17. Tavis JE, Ganem D. 1996. Evidence for activation of the hepatitis B virus polymerase by binding of its RNA template. J. Virol. 70:5741-5750.
18. Tavis JE, Massey B, Gong Y. 1998. The duck hepatitis B virus polymerase is activated by its RNA packaging signal, epsilon. J. Virol. 72:5789-5796.
19. Wang X, Hu J. 2002. Distinct requirement for two stages of proteinprimed initiation of reverse transcription in hepadnaviruses. J. Virol. 76: 5857-5865.
20. Lin L, Wan F, Hu J. 2008. Functional and structural dynamics of hepadnavirus reverse transcriptase during protein-primed initiation of reverse transcription: effects of metal ions. J. Virol. 82:5703-5714.
21. Abraham TM, Loeb DD. 2007. The topology of hepatitis B virus pregenomic RNA promotes its replication. J. Virol. 81:11577-11584.
22. Scaglione SJ, Lok AS. 2012. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology 142:1360-1368.
23. De Clercq E, Ferir G, Kaptein S, Neyts J. 2010. Antiviral treatment of chronic hepatitis B virus (HBV) infections. Viruses 2:1279-1305.
24. Zoulim F, Locarnini S. 2009. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137:1593-1608.
25. Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. 1997. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob. Agents Chemother. 41:1444-1448.
26. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ. 2009. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleosidenaive patients is rare through 5 years of therapy. Hepatology 49:1503-1514.
27. Seifer M, Hamatake RK, Colonno RJ, Standring DN. 1998. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob. Agents Chemother. 42:3200-3208.
28. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Schall RA, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. 2013. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381:468-475.
29. Delaney WE, Ray AS, Yang H, Qi X, Xiong S, Zhu Y, Miller MD. 2006. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob. Agents Chemother. 50:2471-2477.
30. Staschke KA, Colacino JM. 1994. Priming of duck hepatitis B virus reverse transcription in vitro: premature termination of primer DNA induced by the 5=-triphosphate of fialuridine. J. Virol. 68:8265-8269.
31. Chu CK, Ma T, Shanmuganathan K, Wang C, Xiang Y, Pai SB, Yao GQ, Sommadossi JP, Cheng YC. 1995. Use of 2=-fluoro-5-methyl-beta- Larabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob. Agents Chemother. 39:979-981.
32. Balakrishna Pai S, Liu SH, Zhu YL, Chu CK, Cheng YC. 1996. Inhibition of hepatitis B virus by a novel L-nucleoside, 2=-fluoro-5-methyl-beta-L- arabinofuranosyl uracil. Antimicrob. Agents Chemother. 40:380-386.
33. Jang JH, Kim JW, Jeong SH, Myung HJ, Kim HS, Park YS, Lee SH, Hwang JH, Kim N, Lee DH. 2011. Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy. J. Viral Hepat. 18:84-90.
34. Korba BE, Furman PA, Otto MJ. 2006. Clevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo. Expert Rev. Anti Infect. Ther. 4:549-561.
35. Lee HS, Chung YH, Lee K, Byun KS, Paik SW, Han JY, Yoo K, Yoo HW, Lee JH, Yoo BC. 2006. A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 43:982-988.
36. Peek SF, Cote PJ, Jacob JR, Toshkov IA, Hornbuckle WE, Baldwin BH, Wells FV, Chu CK, Gerin JL, Tennant BC, Korba BE. 2001. Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax). Hepatology 33:254-266.
37. Kaplan PM, Greenman RL, Gerin JL, Purcell RH, Robinson WS. 1973. DNA polymerase associated with human hepatitis B antigen. J. Virol. 12: 995-1005.
38. Yao GQ, Liu SH, Chou E, Kukhanova M, Chu CK, Cheng YC. 1996. Inhibition of Epstein-Barr virus replication by a novel L-nucleoside, 2=-fluoro-5-methyl- beta-L-arabinofuranosyluracil. Biochem. Pharmacol. 51:941-947.
39. Lewis W, Meyer RR, Simpson JF, Colacino JM, Perrino FW. 1994. Mammalian DNA polymerases alpha, beta, gamma, delta, and epsilon incorporate fialuridine (FIAU) monophosphate into DNA and are inhibited competitively by FIAU triphosphate. Biochemistry 33:14620-14624.
40. Chong Y, Chu CK. 2002. Understanding the unique mechanism of LFMAU (clevudine) against hepatitis B virus: molecular dynamics studies. Bioorg. Med. Chem. Lett. 12:3459-3462.
41. Jones SA, Hu J. 2013. Protein-primed terminal transferase activity of hepatitis B virus polymerase. J. Virol. 87:2563-2576.
42. Lin L, Hu J. 2008. Inhibition of hepadnavirus reverse transcriptaseepsilon RNA interaction by porphyrin compounds. J. Virol. 82:2305-2312.
43. Hu J, Boyer M. 2006. Hepatitis B virus reverse transcriptase and epsilon RNAsequences required for specific interaction in vitro. J. Virol. 80:2141-2150.
44. Ladner SK, Otto MJ, Barker CS, Zaifert K, Wang GH, Guo JT, Seeger C, King RW. 1997. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob. Agents Chemother. 41:1715-1720.
45. Nguyen DH, Gummuluru S, Hu J. 2007. Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G. J. Virol. 81:4465-4472.
46. Cortes Ledesma F, El Khamisy SF, Zuma MC, Osborn K, Caldecott KW. 2009. A human 5=-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage. Nature 461:674-678.
47. Levine S, Hernandez D, Yamanaka G, Zhang S, Rose R, Weinheimer S, Colonno RJ. 2002. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob. Agents Chemother. 46:2525-2532.
48. Langley DR, Walsh AW, Baldick CJ, Eggers BJ, Rose RE, Levine SM, Kapur AJ, Colonno RJ, Tenney DJ. 2007. Inhibition of hepatitis B virus polymerase by entecavir. J. Virol. 81:3992-4001.
49. De Clercq E. 2010. In search of a selective therapy of viral infections. Antiviral Res. 85:19-24.
50. Sarafianos SG, Marchand B, Das K, Himmel DM, Parniak MA, Hughes SH, Arnold E. 2009. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J. Mol. Biol. 385:693-713.
51. Crotty S, Cameron C, Andino R. 2002. Ribavirin's antiviral mechanism of action: lethal mutagenesis? J. Mol. Med. (Berlin) 80:86-95.
52. Kwon SY, Park YK, Ahn SH, Cho ES, Choe WH, Lee CH, Kim BK, Ko SY, Choi HS, Park ES, Shin GC, Kim KH. 2010. Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients. J. Virol. 84:4494-4503.
53. Das K, Martinez SE, Bauman JD, Arnold E. 2012. HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism. Nat. Struct. Mol. Biol. 19:253-259.
54. Tchesnokov EP, Obikhod A, Schinazi RF, Gotte M. 2008. Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase. J. Biol. Chem. 283:34218-34228.
55. Tuske S, Sarafianos SG, Clark AD, Jr, Ding J, Naeger LK, White KL, Miller MD, Gibbs CS, Boyer PL, Clark P, Wang G, Gaffney BL, Jones RA, Jerina DM, Hughes SH, Arnold E. 2004. Structures of HIV-1 RTDNA complexes before and after incorporation of the anti-AIDS drug tenofovir. Nat. Struct. Mol. Biol. 11:469-474.
56. Niu C, Bao H, Tolstykh T, Micolochick Steuer HM, Murakami E, Korba B, Furman PA. 2010. Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors. Antivir. Ther. 15:401-412.
57. Zhu Y, Curtis M, Qi X, Miller MD, Borroto-Esoda K. 2009. Antihepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/ nucleotide analogues. Antivir. Chem. Chemother. 19:165-176.
58. Galmarini CM, Mackey JR, Dumontet C. 2002. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol. 3:415-424.